Hubei Biocause Pharmaceutical (000627) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.008x

Based on the latest financial reports, Hubei Biocause Pharmaceutical (000627) has a cash flow conversion efficiency ratio of 0.008x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥276.06 Million ≈ $40.40 Million USD) by net assets (CN¥33.70 Billion ≈ $4.93 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Hubei Biocause Pharmaceutical (000627) balance sheet quality index to measure how much of total assets are equity-financed.

Hubei Biocause Pharmaceutical - Cash Flow Conversion Efficiency Trend (2001–2023)

This chart illustrates how Hubei Biocause Pharmaceutical's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Hubei Biocause Pharmaceutical cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Hubei Biocause Pharmaceutical Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hubei Biocause Pharmaceutical ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Topsec Technologies Group Inc
SHE:002212
-0.018x
Shanghai Yaoji Playing Card Co Ltd
SHE:002605
0.044x
AS LHV GROUP EO -10
F:ASU0
N/A
Zhe Jiang Dali Technology Co Ltd
SHE:002214
0.049x
Jiuzhitang Co Ltd
SHE:000989
0.026x
Suzhou Huaya Intelligence Technology Co Ltd
SHE:003043
0.014x
UOA Development Bhd
KLSE:5200
0.005x
Jingjin Environmental Protection Co Ltd
SHG:603279
0.050x

Annual Cash Flow Conversion Efficiency for Hubei Biocause Pharmaceutical (2001–2023)

The table below shows the annual cash flow conversion efficiency of Hubei Biocause Pharmaceutical from 2001 to 2023. For the full company profile with market capitalisation and key ratios, see Hubei Biocause Pharmaceutical market cap and net worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2023-12-31 CN¥33.63 Billion
≈ $4.92 Billion
CN¥9.53 Billion
≈ $1.40 Billion
0.283x +30.37%
2022-12-31 CN¥34.60 Billion
≈ $5.06 Billion
CN¥7.52 Billion
≈ $1.10 Billion
0.217x +95.29%
2021-12-31 CN¥37.47 Billion
≈ $5.48 Billion
CN¥4.17 Billion
≈ $610.58 Million
0.111x -82.02%
2020-12-31 CN¥34.59 Billion
≈ $5.06 Billion
CN¥21.42 Billion
≈ $3.13 Billion
0.619x -25.61%
2019-12-31 CN¥34.35 Billion
≈ $5.03 Billion
CN¥28.60 Billion
≈ $4.19 Billion
0.833x +44.56%
2018-12-31 CN¥26.01 Billion
≈ $3.81 Billion
CN¥14.98 Billion
≈ $2.19 Billion
0.576x +3463.41%
2017-12-31 CN¥26.70 Billion
≈ $3.91 Billion
CN¥431.58 Million
≈ $63.15 Million
0.016x +114.07%
2016-12-31 CN¥20.40 Billion
≈ $2.98 Billion
CN¥-2.34 Billion
≈ $-342.76 Million
-0.115x -338.31%
2015-12-31 CN¥1.78 Billion
≈ $261.01 Million
CN¥-46.73 Million
≈ $-6.84 Million
-0.026x -128.83%
2013-12-31 CN¥1.44 Billion
≈ $210.17 Million
CN¥130.53 Million
≈ $19.10 Million
0.091x +48.97%
2012-12-31 CN¥1.54 Billion
≈ $224.96 Million
CN¥93.79 Million
≈ $13.72 Million
0.061x +28.87%
2011-12-31 CN¥1.41 Billion
≈ $206.93 Million
CN¥66.95 Million
≈ $9.80 Million
0.047x -66.23%
2010-12-31 CN¥1.60 Billion
≈ $234.43 Million
CN¥224.58 Million
≈ $32.86 Million
0.140x +2.40%
2007-12-31 CN¥866.03 Million
≈ $126.73 Million
CN¥118.56 Million
≈ $17.35 Million
0.137x -22.71%
2006-12-31 CN¥723.71 Million
≈ $105.90 Million
CN¥128.19 Million
≈ $18.76 Million
0.177x +166.20%
2005-12-31 CN¥731.23 Million
≈ $107.00 Million
CN¥48.66 Million
≈ $7.12 Million
0.067x -14.08%
2004-12-31 CN¥723.91 Million
≈ $105.93 Million
CN¥56.07 Million
≈ $8.20 Million
0.077x +58.41%
2001-12-31 CN¥762.99 Million
≈ $111.65 Million
CN¥37.30 Million
≈ $5.46 Million
0.049x --

About Hubei Biocause Pharmaceutical

SHE:000627 China Insurance - Life
Market Cap
$1.13 Billion
CN¥7.75 Billion CNY
Market Cap Rank
#8235 Global
#1884 in China
Share Price
CN¥1.58
Change (1 day)
+0.00%
52-Week Range
CN¥1.39 - CN¥1.58
All Time High
CN¥10.45
About

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ethe… Read more